Cargando…

The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study

BACKGROUND: Preclinical evidence shows that short-term fasting (STF) protects healthy cells against side effects of chemotherapy and makes cancer cells more vulnerable to it. This pilot study examines the feasibility of STF and its effects on tolerance of chemotherapy in a homogeneous patient group...

Descripción completa

Detalles Bibliográficos
Autores principales: de Groot, Stefanie, Vreeswijk, Maaike PG, Welters, Marij JP, Gravesteijn, Gido, Boei, Jan JWA, Jochems, Anouk, Houtsma, Daniel, Putter, Hein, van der Hoeven, Jacobus JM, Nortier, Johan WR, Pijl, Hanno, Kroep, Judith R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4595051/
https://www.ncbi.nlm.nih.gov/pubmed/26438237
http://dx.doi.org/10.1186/s12885-015-1663-5
_version_ 1782393525657141248
author de Groot, Stefanie
Vreeswijk, Maaike PG
Welters, Marij JP
Gravesteijn, Gido
Boei, Jan JWA
Jochems, Anouk
Houtsma, Daniel
Putter, Hein
van der Hoeven, Jacobus JM
Nortier, Johan WR
Pijl, Hanno
Kroep, Judith R
author_facet de Groot, Stefanie
Vreeswijk, Maaike PG
Welters, Marij JP
Gravesteijn, Gido
Boei, Jan JWA
Jochems, Anouk
Houtsma, Daniel
Putter, Hein
van der Hoeven, Jacobus JM
Nortier, Johan WR
Pijl, Hanno
Kroep, Judith R
author_sort de Groot, Stefanie
collection PubMed
description BACKGROUND: Preclinical evidence shows that short-term fasting (STF) protects healthy cells against side effects of chemotherapy and makes cancer cells more vulnerable to it. This pilot study examines the feasibility of STF and its effects on tolerance of chemotherapy in a homogeneous patient group with early breast cancer (BC). METHODS: Eligible patients had HER2-negative, stage II/III BC. Women receiving (neo)-adjuvant TAC (docetaxel/doxorubicin/cyclophosphamide) were randomized to fast 24 h before and after commencing chemotherapy, or to eat according to the guidelines for healthy nutrition. Toxicity in the two groups was compared. Chemotherapy-induced DNA damage in peripheral blood mononuclear cells (PBMCs) was quantified by the level of γ-H2AX analyzed by flow cytometry. RESULTS: Thirteen patients were included of whom seven were randomized to the STF arm. STF was well tolerated. Mean erythrocyte- and thrombocyte counts 7 days post-chemotherapy were significantly higher (P = 0.007, 95 % CI 0.106-0.638 and P = 0.00007, 95 % CI 38.7-104, respectively) in the STF group compared to the non-STF group. Non-hematological toxicity did not differ between the groups. Levels of γ-H2AX were significantly increased 30 min post-chemotherapy in CD45 + CD3- cells in non-STF, but not in STF patients. CONCLUSIONS: STF during chemotherapy was well tolerated and reduced hematological toxicity of TAC in HER2-negative BC patients. Moreover, STF may reduce a transient increase in, and/or induce a faster recovery of DNA damage in PBMCs after chemotherapy. Larger studies, investigating a longer fasting period, are required to generate more insight into the possible benefits of STF during chemotherapy. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01304251, March 2011 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1663-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4595051
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45950512015-10-07 The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study de Groot, Stefanie Vreeswijk, Maaike PG Welters, Marij JP Gravesteijn, Gido Boei, Jan JWA Jochems, Anouk Houtsma, Daniel Putter, Hein van der Hoeven, Jacobus JM Nortier, Johan WR Pijl, Hanno Kroep, Judith R BMC Cancer Research Article BACKGROUND: Preclinical evidence shows that short-term fasting (STF) protects healthy cells against side effects of chemotherapy and makes cancer cells more vulnerable to it. This pilot study examines the feasibility of STF and its effects on tolerance of chemotherapy in a homogeneous patient group with early breast cancer (BC). METHODS: Eligible patients had HER2-negative, stage II/III BC. Women receiving (neo)-adjuvant TAC (docetaxel/doxorubicin/cyclophosphamide) were randomized to fast 24 h before and after commencing chemotherapy, or to eat according to the guidelines for healthy nutrition. Toxicity in the two groups was compared. Chemotherapy-induced DNA damage in peripheral blood mononuclear cells (PBMCs) was quantified by the level of γ-H2AX analyzed by flow cytometry. RESULTS: Thirteen patients were included of whom seven were randomized to the STF arm. STF was well tolerated. Mean erythrocyte- and thrombocyte counts 7 days post-chemotherapy were significantly higher (P = 0.007, 95 % CI 0.106-0.638 and P = 0.00007, 95 % CI 38.7-104, respectively) in the STF group compared to the non-STF group. Non-hematological toxicity did not differ between the groups. Levels of γ-H2AX were significantly increased 30 min post-chemotherapy in CD45 + CD3- cells in non-STF, but not in STF patients. CONCLUSIONS: STF during chemotherapy was well tolerated and reduced hematological toxicity of TAC in HER2-negative BC patients. Moreover, STF may reduce a transient increase in, and/or induce a faster recovery of DNA damage in PBMCs after chemotherapy. Larger studies, investigating a longer fasting period, are required to generate more insight into the possible benefits of STF during chemotherapy. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01304251, March 2011 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1663-5) contains supplementary material, which is available to authorized users. BioMed Central 2015-10-05 /pmc/articles/PMC4595051/ /pubmed/26438237 http://dx.doi.org/10.1186/s12885-015-1663-5 Text en © de Groot et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
de Groot, Stefanie
Vreeswijk, Maaike PG
Welters, Marij JP
Gravesteijn, Gido
Boei, Jan JWA
Jochems, Anouk
Houtsma, Daniel
Putter, Hein
van der Hoeven, Jacobus JM
Nortier, Johan WR
Pijl, Hanno
Kroep, Judith R
The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study
title The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study
title_full The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study
title_fullStr The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study
title_full_unstemmed The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study
title_short The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study
title_sort effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in her2-negative breast cancer patients: a randomized pilot study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4595051/
https://www.ncbi.nlm.nih.gov/pubmed/26438237
http://dx.doi.org/10.1186/s12885-015-1663-5
work_keys_str_mv AT degrootstefanie theeffectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy
AT vreeswijkmaaikepg theeffectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy
AT weltersmarijjp theeffectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy
AT gravesteijngido theeffectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy
AT boeijanjwa theeffectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy
AT jochemsanouk theeffectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy
AT houtsmadaniel theeffectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy
AT putterhein theeffectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy
AT vanderhoevenjacobusjm theeffectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy
AT nortierjohanwr theeffectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy
AT pijlhanno theeffectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy
AT kroepjudithr theeffectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy
AT degrootstefanie effectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy
AT vreeswijkmaaikepg effectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy
AT weltersmarijjp effectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy
AT gravesteijngido effectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy
AT boeijanjwa effectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy
AT jochemsanouk effectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy
AT houtsmadaniel effectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy
AT putterhein effectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy
AT vanderhoevenjacobusjm effectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy
AT nortierjohanwr effectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy
AT pijlhanno effectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy
AT kroepjudithr effectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy